[The incidence of bladder tumor recurrences after transurethral resection during combined treatment].
A total of 231 patients undergoing transurethral resection combined with intravesical chemotherapy were examined for incidence of vesical tumor relapses. Some patients were subjected only to transurethral resection (Group I), those had the resection followed by intravesical adriamycin (Group II), those underwent the resection followed by thiophosphamide chemical prevention (Group III), and those had surgeries after intravesical chemotherapy (Group IV). The incidence of the relapses was 44, 43.1, 29.6, and 52.9%, respectively. The incidence of relapses was examined in relation to the type, malignancy, and multiple foci of the tumor.
B P
BP
Matveev
V I
VI
Shipilov
D T
DT
Gotsadze
K O
KO
Abdushelishvili
G G
GG
Pirtskhalaishvili
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology* / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000453:epidemiology* / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000628:therapy; D010212:Papilloma / Q000453:epidemiology* / Q000628:therapy; D011182:Postoperative Care; D012086:Reoperation; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology* / Q000628:therapy
Chastota retsidivov opukholeĭ mochevogo puzyria posle transuretral'noĭ rezektsii pri kombinirovannom lechenii.